Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Peer-reviewed

Research Article

Influencing factors of stroke in patients with type 2 diabetes: A systematic review and meta-analysis

  • Mengjiao Zhao,

    Roles Conceptualization, Methodology, Software, Visualization, Writing – original draft, Writing – review & editing

    Affiliation School of Nursing, Zhejiang Chinese Medical University, Hangzhou, 310053, China

    ⨯
  • Yongze Dong,

    Roles Funding acquisition, Methodology, Supervision, Writing – review & editing

    Affiliation Department of Nursing, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, 310014, China

    ⨯
  • Luchen Chen,

    Roles Methodology, Software, Visualization

    Affiliation School of Nursing, Zhejiang Chinese Medical University, Hangzhou, 310053, China

    ⨯
  • Huajuan Shen

    Roles Funding acquisition, Methodology, Project administration, Supervision, Writing – review & editing

    shj13588158842@163.com (SHJ)

    Affiliation Department of Nursing, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, 310014, China

    ⨯

Abstract

Background

Stroke stands as a significant macrovascular complication among individuals with Type 2 diabetes mellitus (T2DM), often resulting in the primary cause of mortality and disability within this patient demographic. Presently, numerous studies have been conducted to investigate the underlying causes of stroke in individuals with T2DM, yet the findings exhibit inconsistencies.

Objective

This paper aims to consolidate and summarize the available evidence concerning the influential factors contributing to stroke among patients diagnosed with T2DM.

Methods

We conducted a comprehensive search across multiple databases, including Cochrane Library, PubMed, Web Of Science, Embase, China Biology Medicine (CBM), China National Knowledge Infrastructure (CNKI), Wanfang and Weipu up to August 2023. Google Scholar was also searched to retrieve gray literature. We calculated odds ratios (OR) and 95% confidence intervals (CI) using Stata software.

Results

Our analysis encompassed 43 observational studies, exploring factors across sociodemographic, biochemical, complications, and hypoglycemic agent categories. The findings identified several risk factors for stroke in patients with T2DM: age, gender, T2DM duration, hypertension, body-mass index (BMI), smoking, Glycated hemoglobin (HbA1c), estimated Glomerular Filtration Rate (eGFR), albuminuria, Triglycerides (TG), Low density lipoprotein cholesterol (LDL-C), Coronary heart disease (CHD), Atrial fibrillation (AF), diabetic retinopathy (DR), Peripheral vascular disease (PVD), and carotid plaque. Conversely, exercise, High density lipoprotein cholesterol (HDL-C), metformin (MET), pioglitazone, and metformin combination therapy emerged as protective factors.

Conclusion

This study underscores the multitude of influencing factors contributing to stroke in people with T2DM patients, among which the microvascular complications of T2DM play an most important role. Therefore, we emphasize the importance of screening for microvascular complications in patients with T2DM. However, due to limitations arising from the number of articles reviewed, there remain areas where clarity is lacking. Further research efforts are warranted to expand upon and reinforce our current findings.

Citation: Zhao M, Dong Y, Chen L, Shen H (2024) Influencing factors of stroke in patients with type 2 diabetes: A systematic review and meta-analysis. PLoS ONE 19(6): e0305954. https://doi.org/10.1371/journal.pone.0305954

Editor: Jacopo Sabbatinelli, Universita Politecnica delle Marche, ITALY

Received: February 8, 2024; Accepted: June 9, 2024; Published: June 24, 2024

Copyright: © 2024 Zhao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the manuscript and its Supporting Information files.

Funding: This work was supported by the General Project of Zhejiang Medical and Health Science and Technology Plan (Grant No.2021KY468 and Grant No.2021KY066). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

1. Introduction

T2DM currently affects an estimated 10.5% (536.6 million) of the global population, a figure expected to escalate to 12.2% (783.2 million) by 2045, as projected by the International Diabetes Federation [1]. This chronic condition predisposes individuals to various macrovascular and microvascular complications, significantly contributing to mortality rates worldwide [2–3]. Stroke, among the prevalent macrovascular complications associated with T2DM, accounted for 6.55 million fatalities in 2019, securing its place as the second leading cause of death globally [4]. Notably, individuals with diabetes face a two to four fold increased risk of stroke compared to their nondiabetic counterparts. Moreover, diabetic patients tend to experience exacerbated post-stroke outcomes and possess a heightened susceptibility to stroke recurrence [5–6].

The occurrence of stroke in T2DM patients results from a convergence of factors including age, gender, hypertension, smoking, dyslipidemia, and more [7–9]. Recent studies indicate a predictive relationship between T2DM microvascular complications such as diabetic nephropathy (DN), DR, diabetic neuropathy, and the likelihood of stroke [10]. Furthermore, emerging evidence recognizes the cardiovascular protective properties of novel hypoglycemic drugs like sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) [11]. However, the existing body of research on stroke causation in T2DM patients exhibits variations in focus, population demographics, sample sizes, and consequent disparate findings.

Therefore, we conducted the current systematic review and meta-analysis to review the influencing factors of stroke in patients with T2DM worldwide and explore the strengths of such associations for early identification and prevention of stroke.

2. Methods

This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [12]. The study was registered in the "International Prospective Register of Systematic Reviews" (PROSPERO) on November 20, 2023 (CRD42023480426).

2.1 Search strategy

Articles were searched on eight electronic databases, including PubMed, Web Of Science, Embasse, Cochrane Library, CBM, CNKI, Weipu and Wanfang database. Gray literature was researched in Google Scholar. We performed the search strategy until August 2023. A combination of MeSH terms and free terms related to “Diabetes Mellitus, Type 2 OR Diabetes Mellitus, Type II OR Type 2 Diabetes Mellitus OR Type 2 Diabetes OR Diabetes, Type 2 OR Diabetes Mellitus, Noninsulin-Dependent OR Diabetes Mellitus, Non Insulin Dependent OR Diabetes Mellitus, Non-Insulin-Dependent OR Non-Insulin-Dependent Diabetes Mellitus”, “Strokes OR Stroke OR Cerebrovascular Accident* OR Cerebrovascular Apoplexy OR Apoplexy, Cerebrovascular OR Vascular Accident, Brain OR Brain Vascular Accident* OR Cerebral Stroke* OR Apoplexy OR Stroke, Acute OR Acute Cerebrovascular Accident OR Hemorrhagic Stroke* OR Ischemic Stroke* OR Acute Ischemic Stroke* OR Thrombotic Stroke* OR Embolic Stroke* OR Cerebral Infarction*”, “risk factors OR risk factor OR influence factor* OR relevant factor*” were used to search. (S1 Table in S1 Appendix)

2.2 Inclusion and exclusion criteria

Studies that reported possible influencing factors of stroke in patients with T2DM were selected based on these inclusion criteria: (1) Patient age ≥ 18 years; (2) observational study (case control, cohort and cross-sectional study); (3) studies that provide the OR with 95% CI, or can be calculated with sufficient information. (4) English or Chinese article. Studies were excluded if they were: (1) duplicate literature; (2) case reports, reviews, conference abstracts, systematic reviews; (3) incomplete or unavailable literature.

2.3 Quality assessment

Two researchers, Mengjiao Zhao and Luchen Chen, independently evaluated article quality using the Newcastle-Ottawa Scale (NOS) for cohort and case-control studies (score ≥ 7 considered high quality) [13], and the criteria of America Agency for Healthcare Research and Quality (AHRQ) for cross-sectional studies (score ≥ 8 considered high quality) [14]. In the case of uncertainty or disagreement about quality, the article was reviewed by a third researcher, Yongze Dong.

2.4 Data extraction

Data extraction was performed by Mengjiao Zhao and Luchen Chen using a standardized form, encompassing details like author, publication year, country, study type, sample size, influencing factors, and adjusted OR with 95% CI for potential confounding variables. Consensus was reached in cases of disagreement through group discussion.

2.5 Data synthesis and statistical analysis

Stata 15.1 software facilitated data analysis, computing pooled OR with 95% CI. A significance level of P < 0.05 was applied. Heterogeneity was assessed using Cochran Q and I2 statistics, adopting a fixed-effects model in the absence of significant heterogeneity (P > 0.10 and I2 ≤ 50%). Otherwise, a random-effects model was employed. Subgroup and sensitivity analyses were performed to explore heterogeneity causes. We analysed subgroups by study area, sample size, type of study design and different classes of influencing factors. Additionally, sensitivity analyses by iteratively removing one study at a time. Egger’s linear regression test gauged publication bias (P > 0.05 indicates no significant publication bias; P < 0.05 suggests publication bias).

3. Results

3.1 Search results

As shown in Fig 1. In total, 13,827 articles were initially identified, with 2,887 duplicates removed. After screening titles and abstracts, 10,771 papers were excluded. A full-text assessment of 169 studies followed, resulting in the exclusion of 126 ineligible studies. Ultimately, 43 studies met the eligibility criteria for inclusion [15–57].

thumbnail
Download:
Fig 1. PRISMA flow diagram of study selection and inclusion process.

https://doi.org/10.1371/journal.pone.0305954.g001

3.2. Characteristics of the included studies

Table 1 showcases the essential features of the 43 incorporated articles, spanning publication years from 2001 to 2023. The studies comprised 28 cohort studies, 8 case-control studies, and 7 cross-sectional studies. Among these, 22 were conducted in developed nations (USA, UK, Australia, Denmark, New Zealand, Spain, Korea, Japan) and 21 in developing countries (China, Saudi Arabia). The sample sizes varied from 96 [30] to 1,297,131 [29], totaling 2,730,010 participants. The quality assessment showed a literature quality assessment score of 7–9 for cohort and case-control studies and 8–10 for cross-sectional studies. (S2-S4 Table in S1 Appendix)

thumbnail
Download:
Table 1. Characteristics of the included studies.

https://doi.org/10.1371/journal.pone.0305954.t001

3.3. Meta-analysis for influencing factors

The meta-analysis encompassed 22 influencing factors categorized into sociodemographic factors, biochemical factors, complications, and hypoglycemic agents. Among the sociodemographic factors are age [15–26], gender [15,17,20,27–28], course of T2DM [15,20,23,29,31], hypertension [15,20–22,28,30,32–35], BMI [15,19–20,33], smoking [15,17,24,29,33,36] and exercise [29,33,36]; Biochemical indexes are HbA1c [15,17,22,30,37], eGFR [16,19,22,38–39], TC [16,25,30–31], TG [16,19,24], Albuminuria [16,31,40–41], HDL-C [19,42] and LDL-C [19,42]; Complications are CHD [27,29,35], AF [16,29,31,35,41,43], DR [16,41,44], PVD [21,24,45] and carotid plaque [23,32], as well as hypoglycemic agents are MET [46–47], pioglitazone [48–49] and MET combination therapy [50–53]. Among the four categories, the pooled OR of complications was the highest (2.09, 95% CI: 1.44–3.05), followed by sociodemographic factors (1.37, 95% CI: 1.14–1.65) and biochemical factors (1.28, 95% CI: 1.05–1.57), while the hypoglycemic agents was the lowest (0.63, 95% CI: 0.46–0.85), which was a protective factor. The details are shown in Table 2. In addition, the forest plot containing all the influencing factors is shown in Fig 2.

thumbnail
Download:
Table 2. The results of factors associated with stroke in the patients with T2DM.

https://doi.org/10.1371/journal.pone.0305954.t002

thumbnail
Download:
Fig 2. The forest plot of all influencing factors associated with stroke in patients with T2DM.

https://doi.org/10.1371/journal.pone.0305954.g002

3.3.1 Sociodemographic factors.

A study of 22 articles exploring the correlation between sociodemographic factors and stroke in T2DM patients highlighted age, hypertension, and duration of T2DM as frequently studied factors. Notably, hypertension demonstrated the highest pooled OR (2.71, 95% CI: 2.41–3.04), followed by smoking (1.65, 95% CI: 1.60–2.97). Additionally, factors such as longer T2DM duration (1.46, 95% CI: 1.28–1.67), male gender (1.40, 95% CI: 1.34–1.46), BMI (1.18, 95% CI: 1.14–1.23), and age (1.10, 95% CI: 1.06–1.13) were associated with higher stroke risk. Conversely, exercise exhibited a protective effect (0.77, 95% CI: 0.69–0.86).

3.3.2 Biochemical factors.

Among 17 articles investigating biochemical factors, LDL-C exhibited the highest pooled OR (3.41, 95% CI: 1.81–6.41), followed by eGFR (2.15, 95% CI: 1.81–2.55) and albuminuria (1.32, 95% CI: 1.17–1.49). Other factors, including TG (1.16, 95% CI: 1.06–1.26) and HbA1c (1.09, 95% CI: 1.07–1.11), were identified as risk factors for stroke, whereas HDL-C (0.14, 95% CI: 0.05–0.39) appeared protective. However, TC (0.90, 95% CI: 0.59–1.37) was not significantly associated with stroke in T2DM patients.

3.3.3 Complications.

The analysis of 13 studies exploring complications and stroke revealed CHD (2.92, 95% CI: 1.35–6.30), PVD (2.84, 95% CI: 1.86–4.34), and AF (2.76, 95% CI: 2.56–2.97) as factors with the highest pooled OR. DR(1.59, 95% CI: 1.35–1.88) and carotid plaque (1.36, 95% CI: 1.14–1.62) were also linked to increased stroke risk.

3.3.4 Hypoglycemic agents.

Exploring hypoglycemic agents across 8 articles, MET combination therapy (0.74, 95% CI: 0.66–0.83) and pioglitazone (0.72, 95% CI: 0.64–0.81) showed similar pooled OR, indicating a protective effect. In contrast, MET alone exhibited the lowest pooled OR (0.47, 95% CI: 0.43–0.52).

3.3.5 Other factors.

In addition to the factors noted above, several variables have shown significant associations with stroke occurrences in patients with T2DM. These factors include central obesity [25] (2.07, 95% CI: 1.39–3.09), inadequate sleep duration [33] (< 6h/ day: 1.44, 95% CI: 1.20–1.73; > 8h/ day: 1.22, 95% CI: 1.05–1.42), obstructive sleep apnea [54] (1.57, 95% CI: 1.27–1.94), lower educational attainment [28] (2.60, 95% CI: 1.20–5.80), alcohol misuse [24] (2.60, 95% CI: 1.20–5.80), degree of cerebral artery stenosis [32] (4.77, 95% CI: 2.60–9.81), diabetic neuropathy [16] (1.73, 95% CI: 1.14–2.64), congestive heart failure [18] (2.08, 95% CI: 1.26–3.42), and SU [55] (as compared to MET: 3.23, 95% CI: 3.01–3.45). Furthermore, Free triiodothyronine [32] (0.36, 95% CI: 0.20–0.64), SGLT2-i [56] (0.85, 95% CI: 0.82–0.88), and GLP-1RA [57] (0.82, 95% CI: 0.74–0.91) have demonstrated negative correlations.

3.3.6 Subgroup analysis.

Subgroup analysis was performed on five factors exhibiting high heterogeneity, excluding HDL-C and LDL-C due to the limited number of included articles. These factors comprised age, HbA1c, duration of T2DM, exercise, TC, and CHD. Age was categorized into three subgroups: >75 years old, 65–75 years old, and <65 years old (Fig 3). The duration of T2DM was divided into two subgroups, with exclusion of “Ye 2016” [23] due to unclear reporting: >5 years and >10 years (Fig 4). HbA1c was stratified into two subgroups: 7%-9% and >9% (Fig 5). Sensitivity analyses were employed for subgroups exhibiting persistent high heterogeneity, and specifics are outlined in Table 3.

thumbnail
Download:
Fig 3. The forest plot of subgroup analysis for age.

https://doi.org/10.1371/journal.pone.0305954.g003

thumbnail
Download:
Fig 4. The forest plot of subgroup analysis for the duration of T2DM.

https://doi.org/10.1371/journal.pone.0305954.g004

thumbnail
Download:
Fig 5. The forest plot of subgroup analysis for HbA1c.

https://doi.org/10.1371/journal.pone.0305954.g005

thumbnail
Download:
Table 3. The results of subgroup analysis.

https://doi.org/10.1371/journal.pone.0305954.t003

3.3.7 Sensitivity analysis.

To evaluate the robustness of the association results, we performed a sensitivity analysis by iteratively removing one study at a time and recalculating the summary OR.(S1 Fig in S1 Appendix)

Among the influencing factors, the study by “Xu 2022” [15] exhibited notable impacts on hypertension-related heterogeneity. Upon its exclusion, the pooled OR was found to be 2.71 (2.41, 3.04), with a substantial reduction in heterogeneity (I2 = 0%, p = 0.45). Similarly, concerning smoking, exclusion of the same study (“Xu 2022” [15]) resulted in a pooled OR of 1.65 (1.60, 1.69), accompanied by a significant decrease in heterogeneity (I2 = 0%, p = 0.82). Furthermore, when considering eGFR, exclusion of the study by “Shi 2020” [19] led to a pooled OR of 2.15 (1.81, 2.55), along with a marked reduction in heterogeneity (I2 = 0%, p = 0.55). Additionally, the study by “Chan(1) 2018” [51] affected heterogeneity in MET combination therapy; its exclusion notably decreased heterogeneity (I2 = 0%, p = 0.48), yielding a pooled OR of 0.74 (0.66, 0.83).

In the sensitivity analysis, the study conducted by “Niwa 2019” [21] significantly impacted the heterogeneity related to Age 65–75 years. Upon its exclusion, the pooled OR was 1.74 (1.46, 2.08), accompanied by a substantial reduction in heterogeneity (I2 = 0%, p = 0.54). Apart from these instances, no significant changes in pooled OR were observed for the other influencing factors, indicating the stability and reliability of our results.

3.3.8 Publication bias.

Egger’s test was utilized to assess publication bias within the study. Notably, the P-values obtained from Egger’s test were greater than 0.05 for all exposure variables, except for age (P = 0.000), albuminuria (P = 0.016), and age < 65 years (P = 0.020). These outcomes suggest the presence of publication bias specifically in relation to age, albuminuria, and age < 65 years. Further details regarding these findings are available in Table 2 and Table 3.

4. Disscussion

4.1 Discussion of the main results

This study delved into a comprehensive exploration of stroke risk factors in patients with T2DM across sociodemographic factors, biochemical factors, complications, and hypoglycemic agent categories. Within these categories, 16 (76%) factors were identified as risk indicators, while 5 (24%) were identified as protective factors through meta-analyses.

Our investigation revealed that sociodemographic and biochemical factors have been extensively studied, among these factors, age emerged as a crucial factor influencing stroke risk in T2DM patients. Subgroup analysis revealed an increasing stroke risk with advancing age, consistent with prior research [58] indicating a higher stroke risk among elderly T2DM patients due to declining bodily functions and the prevalence of cardiovascular risk factors like hypertension and microvascular complications. The timing of T2DM diagnosis was inversely linked to cardiovascular risk [59–60], suggesting the need for heightened vigilance among patients diagnosed at younger ages. Gender-based differences in stroke risk presented conflicting findings. While certain studies [61] suggested a higher risk in women, others [62] indicated the opposite. These disparities might relate to cultural and racial variations among study populations. Additionally, hypertension was strongly associated with an increased risk of stroke in T2DM patients, aligning with previous research [60] attributing this to metabolic syndrome, insulin resistance, and related cardiovascular damage [63]. The duration of T2DM proved to be an independent risk factor for stroke [64]. Studies [5] highlighted a consistent increase in stroke risk with prolonged T2DM duration, the risk of stroke increased by 3% per year in patients with T2DM duration ≥10 years, potentially linked to exacerbated atherosclerosis and endothelial dysfunction. Smoking was identified as another contributor to heightened stroke risk in T2DM patients [65], with evidence supporting smoking cessation as a means of reducing this risk, and smoking cessation in patients with T2DM reduces the risk of ischemic stroke by 20% [66]. Moreover, BMI exhibited a linear relationship with cardiovascular disease risk, with every 5-unit BMI increase correlating with a 9% rise in cardiovascular risk [67]. This association was attributed to obesity-related dyslipidemia, promoting insulin resistance and fostering atherosclerosis [68]. However, other studies have pointed out that insulin resistance reduces the incidence and mortality of cardiovascular disease in obese patients. This self-contradictory conclusion suggests that the induction of insulin resistance may be a physiological adaptation process. Therefore, it is suggested that health care providers should pay more attention to daily nutrition management and physical exercise to reduce the risk of stroke in obese and dyslipidemia patients with T2DM, instead of relying on high doses of insulin and sulfonylurea medications [69]. In addition, higher levels of HbA1c correlated positively with increased stroke risk, especially among patients with HbA1c levels above 9% [70–71]. This underlines the importance of glycemic control in preventing stroke. Although the effect of intensive glycemic control on cardiovascular disease is still controversial, studies have shown that the reduction of HbA1c and the prolongation of intensive glycemic control may have a positive effect on cardiovascular disease [72].

An important finding of this study was that complications arising from T2DM were identified as the most robust indicators of stroke risk. Atherosclerosis, aggravated by T2DM, notably increased the risk of stroke, especially in patients with large artery atherosclerosis [5]. Microvascular complications such as DR, DN, and diabetic neuropathy emerged as significant predictors of future macrovascular diseases. And after adjusting for traditional risk factors, DR and DN are still independent predictors of stroke in patients with T2DM [73–74]. Additionally, AF was identified as a substantial risk factor for stroke in T2DM patients [75]. Macrovascular and microvascular complications of T2DM are the main causes of disability and death in patients. However, Due to the long duration of pre-diabetes in most patients, many patients have macrovascular and microvascular damage before the onset of overt diabetes occurs [61,76]. Therefore, for people with diabetes risk factors and genetic susceptibility, health care personnel should carefully assess their macrovascular and microvascular changes and guide them to follow a healthy lifestyle to prevent or timely detect macrovascular and microvascular complications. In addition, it is deemed essential for future articles to find new predictors such as biomarkers and related gene induction studies [77].

Another finding of this study was MET, Pioglitazone, and MET combination therapy were protective factors against stroke in T2DM patients. The cardiovascular protective effects of MET and pioglitazone have been confirmed in previous studies, but for patients with existing cardiovascular diseases, there is insufficient evidence to rely on monotherapy [76]. One research [78] have shown that MET combination therapy can better control blood glucose, while reducing the risk of late glycemic control failure, and did not increase hypoglycemic events. It appears that our findings differ because the included article in our study compared MET combination therapy with MET + SU, rather than directly contrasting it with MET monotherapy. Otherwise, the American Diabetes Association and the European Association for the Study of Diabetes [79] recommend SGLT2-i or GLP-1RA as hypoglycemic agents for patients at high risk of cardiovascular disease, and studies [11] have shown that SGLT2-i or GLP-1RA may reduce the risk of stroke in patients with T2DM. Nonetheless, given the limited number of articles included, there is not adequate evidence to conclusively support these findings. Consequently, there is a clear indication for additional large-scale prospective studies to validate and further substantiate these conclusions in the future.

In summary, stroke occurrence in T2DM patients is multifactorial, influenced by a spectrum of variables. Beyond conventional pharmacological approaches, the cultivation of enduring healthy habits, including adherence to a well-rounded nutritional regimen, cessation of smoking, and consistent engagement in physical exercise, stands as imperative in averting stroke incidents [79]. As personalized medicine advances, preventing strokes in T2DM necessitates a holistic approach, leveraging accurate personalized risk prediction models powered by algorithms. We anticipate this study to serve as a reference point for enhancing related risk prediction models. Significantly, our analysis solely scrutinized hypoglycemic agents. Hence, to devise a more comprehensive strategy for managing T2DM, there exists an urgent imperative to delve deeper into the interrelationships among diverse medications, including antihypertensive agents, lipid-lowering medications, antiplatelet therapies, and multifaceted drug regimens concerning stroke occurrences in individuals with T2DM. This holistic exploration would markedly enhance our comprehension and fortify therapeutic approaches aimed at addressing the complexities of managing T2DM complications, specifically in the context of reducing the peril associated with strokes.

4.2 Strengths and weaknesses

The strengths of our systematic review consist of the included articles are high-quality. Moreover, we specifically analyzed the complications and hypoglycemic medications of T2DM patients. This can offer a more comprehensive reference for the holistic management of stroke risk in T2DM patients. In addition, some potentially modifiable risk factors offers actionable insights into preventive strategies.

However, several limitations in this review merit acknowledgment. Firstly, observational studies inherently carry confounding factors. While we extracted multivariate adjusted OR, the likelihood of other unmeasured factors influencing the actual relationships cannot be dismissed. Secondly, although numerous factors were explored, the limited number of individual studies impedes a comprehensive elucidation of crucial factors contributing to the heterogeneity in research outcomes, such as regional disparities, racial influences, and sample sizes. Furthermore, the predominance of studies from Asian regions raises concerns about the generalizability and representativeness of the results. Moreover, not all articles included were prospective studies, which curtails establishing a definitive causal relationship between outcomes and variables. Hence, the results should be interpreted cautiously, considering these limitations.

5. Conclusion

This comprehensive review and meta-analysis identified several prominent risk factors associated with stroke in patients diagnosed with T2DM. Age, gender, T2DM duration, hypertension, dyslipidemia, smoking habits, elevated HbA1c levels, and various T2DM-related complications such as CHD, DR, AF, DN, PVD, and carotid plaque were all identified as significant risk factors. Conversely, exercise, HDL-C, and certain hypoglycemic agents demonstrated a protective effect against stroke in these patients. Healthcare practitioners can leverage these findings to develop targeted prevention strategies for individuals with T2DM. Beyond advocating for lifestyle improvements, proactive screening for both macrovascular and microvascular complications is crucial. Additionally, the judicious adjustment of hypoglycemic medications holds promise in mitigating stroke risk in this patient population.

Acknowledgments

We really appreciate the efforts of all the researchers whose articles were included in this study.

References

  1. 1. SUN H, SAEEDI P, KARURANGA S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract, 2022, 183: 109119. pmid:34879977
  2. 2. ZHENG Y, LEY S H, HU F B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol, 2018, 14(2): 88–98. pmid:29219149
  3. 3. LING W, HUANG Y, HUANG Y M, et al. Global trend of diabetes mortality attributed to vascular complications, 2000–2016. Cardiovasc Diabetol, 2020, 19(1): 182. pmid:33081808
  4. 4. COLLABORATORS G S. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol, 2021, 20(10): 795–820. pmid:34487721
  5. 5. MOSENZON O, CHENG A Y, RABINSTEIN A A, et al. Diabetes and Stroke: What Are the Connections?. J Stroke, 2023, 25(1): 26–38. pmid:36592968
  6. 6. TUN N N, ARUNAGIRINATHAN G, MUNSHI S K, et al. Diabetes mellitus and stroke: A clinical update. World J Diabetes, 2017, 8(6): 235–248. pmid:28694925
  7. 7. HASHEMI R, RAHIMLOU M, BAGHDADIAN S, et al. Investigating the effect of DASH diet on blood pressure of patients with type 2 diabetes and prehypertension: Randomized clinical trial [J]. Diabetes Metab Syndr, 2019, 13(1): 1–4. https://doi.org/10.1016/j.dsx.2018.06.014.
  8. 8. RAHIMLU M, SHAB-BIDAR S, DJAFARIAN K. Body Mass Index and All-cause Mortality in Chronic Kidney Disease: A Dose-response Meta-analysis of Observational Studies [J]. J Ren Nutr, 2017, 27(4): 225–232. https://doi.org/10.1053/j.jrn.2017.01.016.
  9. 9. VAHDAT M, HOSSEINI S A, KHALATBARI MOHSENI G, et al. Effects of resistant starch interventions on circulating inflammatory biomarkers: a systematic review and meta-analysis of randomized controlled trials [J]. Nutr J, 2020, 19(1): 33. https://doi.org/10.1186/s12937-020-00548-6.
  10. 10. PENLIOGLOU T, STOIAN A P, PAPANAS N. Diabetes, Vascular Aging and Stroke: Old Dogs, New Tricks?. J Clin Med, 2021, 10(19): 4620. pmid:34640636
  11. 11. RATHMANN W, KOSTEV K. Association of glucose-lowering drugs with incident stroke and transient ischaemic attacks in primary care patients with type 2 diabetes: disease analyzer database. Acta Diabetol, 2022, 59(11): 1443–1451. pmid:35933524
  12. 12. PAGE M J, MCKENZIE J E, BOSSUYT P M, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed), 2021, 74(9): 790–799. https://doi.org/10.1136/bmj.n71.
  13. 13. STANG A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603–605. pmid:20652370
  14. 14. ZENG X, ZHANG Y, KWONG J S, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med, 2015, 8(1): 2–10. pmid:25594108
  15. 15. XU J J, LU X, ZHANG L Y, et al. Investigation and analysis of the prevalence and influencing factors of stroke in patients with type 2 diabetes mellitus in Chengnan Community of Jiaxing City. Pract Prev Med, 2022, 29(11): 1358–1361. https://doi.org/10.3969/j.issn.1006-3110. 2022. 11. 018.
  16. 16. SALINERO-FORT M A, ANDRéS-REBOLLO F J S, CáRDENAS-VALLADOLID J, et al. Cardiovascular risk factors associated with acute myocardial infarction and stroke in the MADIABETES cohort. Sci Rep, 2021, 11(1): 15245. pmid:34315938
  17. 17. IWASE M, KOMORITA Y, OHKUMA T, et al. Incidence of stroke and its association with glycemic control and lifestyle in Japanese patients with type 2 diabetes mellitus: The Fukuoka diabetes registry. Diabetes Res Clin Pract, 2021, 172: 108518. pmid:33096191
  18. 18. ISAMAN D J M, HERMAN W H, YE W. Prediction of transient ischemic attack and minor stroke in people with type 2 diabetes mellitus. J Diabetes Complications, 2021, 35(7): 107911. pmid:33902996
  19. 19. SHI R, ZHANG T, SUN H, et al. Establishment of Clinical Prediction Model Based on the Study of Risk Factors of Stroke in Patients With Type 2 Diabetes Mellitus. Front Endocrinol (Lausanne), 2020, 11: 559. pmid:32982965
  20. 20. SU C, SONG F, WANG Z D, et al. Analysis on prevalence and related factors of old cerebral infarction in patients with type 2 diabetes mellitus. Chin J Prev Contr Chron Dis, 2020, 28(1): 38–41. https://doi.org/10.16386/j.cjpccd.issn.1004-6194.2020.01.009.
  21. 21. NIWA H, TAKAHASHI K, DANNOURA M, et al. The Association of Cardio-Ankle Vascular Index and Ankle-Brachial Index with Macroangiopathy in Patients with Type 2 Diabetes Mellitus. J Atheroscler Thromb, 2019, 26(7): 616–623. pmid:30487347
  22. 22. NOH M, KWON H, JUNG C H, et al. Impact of diabetes duration and degree of carotid artery stenosis on major adverse cardiovascular events: a single-center, retrospective, observational cohort study. Cardiovasc Diabetol, 2017, 16(1): 74. pmid:28587650
  23. 23. YE K X, FAN M L. Analysis of Clinical Features and Relevant Risk Factors of Type II Diabetes Complicated with Ischemic Stroke. Journal of GuiZhou Medical University, 2016, 41(10): 1231–1234+1240. https://doi.org/10.19367/j.cnki.1000-2707.2016.10.026.
  24. 24. LI L, AMBEGAONKAR B M, RECKLESS J P, et al. Association of a reduction in low-density lipoprotein cholesterol with incident cardiovascular and cerebrovascular events among people with type 2 diabetes mellitus. Eur J Prev Cardiol, 2014, 21(7): 855–865. pmid:23460659
  25. 25. LIU X R, ZHOU Y R, WANG J J, et al. Effect of central obesity on the even~of new. onset cerebral infarction among type 2 diabetes mellitus. Chin J Epidemiol, 2014, 35(4): 390–392. https://doi.org/10.3760/cma.j.issn.0254-6450.2014.04.010.
  26. 26. NOMURA K, HAMAMOTO Y, TAKAHARA S, et al. Relationship between carotid intima-media thickness and silent cerebral infarction in Japanese subjects with type 2 diabetes. Diabetes Care, 2010, 33(1): 168–170. pmid:19808915
  27. 27. WU J H, WU Y Q, WU Y, et al. Incidence and risk factors of ischemic stroke in patients with type 2 diabetes among urban workers in Beijing, China. Journal Of Peking University (Health Sciences), 2022, 54(2): 249–254. pmid:35435187
  28. 28. ALRAMADAN M J, MAGLIANO D J, ALHAMRANI H A, et al. Lifestyle factors and macro- and micro-vascular complications among people with type 2 diabetes in Saudi Arabia. Diabetes Metab Syndr, 2019, 13(1): 484–491. pmid:30641750
  29. 29. KIM M K, HAN K, CHO J H, et al. A model to predict risk of stroke in middle-aged adults with type 2 diabetes generated from a nationwide population-based cohort study in Korea. Diabetes Res Clin Pract, 2020, 163: 108157. pmid:32333968
  30. 30. XU B. Risk factor of complicated stroke in patients with type 2 diabetes mellitus. Chinese Journal Of Clinical Rehabilitation, 2004, (16): 3012–3013. https://doi.org/10.3321/j.issn:1673-8225.2004.16.005.
  31. 31. GILLETT , DAVIS W A, JACKSON D, et al. Prospective evaluation of carotid bruit as a predictor of first stroke in type 2 diabetes: the Fremantle Diabetes Study. Stroke, 2003, 34(9): 2145–2151. pmid:12907819
  32. 32. WU H M. Establishment and validation of a predictive model for acute ischemic stroke in elderly patients with type 2 diabetes mellitus [D]. GanSu: LanZhou University, 2022. https://doi.org/10.27204/d.cnki.glzhu.2022.000261.
    • 33. HE C, WANG W, CHEN Q, et al. Factors associated with stroke among patients with type 2 diabetes mellitus in China: a propensity score matched study. Acta Diabetol, 2021, 58(11): 1513–1523. pmid:34125293
    • 34. KOMI R, TANAKA F, OMAMA S, et al. Burden of high blood pressure as a contributing factor to stroke in the Japanese community-based diabetic population. Hypertens Res, 2018, 41(7): 531–538. pmid:29654296
    • 35. MENG Q H, WANG J H, WANG Z L, et al.A study on the risk of factors of cerebral infarction as complication of type 2 diabetes mellitu patients. Chin J Epidemiol, 2001, 22(3):208–211.
    • 36. KIM M K, HAN K, KIM B, et al. Effects of exercise initiation and smoking cessation after new-onset type 2 diabetes mellitus on risk of mortality and cardiovascular outcomes. Sci Rep, 2022, 12(1): 10656. pmid:35739161
    • 37. ELLEY C R, KENEALY T, ROBINSON E, et al. Glycated haemoglobin and cardiovascular outcomes in people with Type 2 diabetes: a large prospective cohort study. Diabet Med, 2008, 25(11): 1295–1301. pmid:19046219
    • 38. SUN X, HE J, JI X L, et al. Association of Chronic Kidney Disease with Coronary Heart Disease and Stroke Risks in Patients with Type 2 Diabetes Mellitus: An Observational Cross-sectional Study in Hangzhou, China. Chin Med J (Engl), 2017, 130(1): 57–63. pmid:28051024
    • 39. WANG Y, KATZMARZYK P T, HORSWELL R, et al. Kidney function and the risk of cardiovascular disease in patients with type 2 diabetes. Kidney Int, 2014, 85(5): 1192–1199. pmid:24107845
    • 40. FANGEL M V, NIELSEN P B, KRISTENSEN J K, et al. Albuminuria and Risk of Cardiovascular Events and Mortality in a General Population of Patients with Type 2 Diabetes Without Cardiovascular Disease: A Danish Cohort Study. Am J Med, 2020, 133(6): e269–e279. pmid:32205071
    • 41. DRINKWATER J J, DAVIS T M E, HELLBUSCH V, et al. Retinopathy predicts stroke but not myocardial infarction in type 2 diabetes: the Fremantle Diabetes Study Phase II. Cardiovasc Diabetol, 2020, 19(1): 43. pmid:32234054
    • 42. GENG L, YAN Z L. Relevant factors of type 2 diabetes patients with cerebral infarction. Chinese Journal of Clinical Nutrition, 2019, 27(3): 161–166. https://doi.org/10.3760/cma.j.issn.1674-635X.2019.03.007.
    • 43. MARFELLA R, SASSO F C, SINISCALCHI M, et al. Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients. J Am Coll Cardiol, 2013, 62(6): 525–530. https://doi.org/10.1016/j.jacc.2013.02.091.
    • 44. MODJTAHEDI B S, WU J, LUONG T Q, et al. Severity of Diabetic Retinopathy and the Risk of Future Cerebrovascular Disease, Cardiovascular Disease, and All-Cause Mortality. Ophthalmology, 2021, 128(8): 1169–1179. pmid:33359888
    • 45. BOUCHI R, BABAZONO T, TAKAGI M, et al. Non-linear association between ankle-brachial pressure index and prevalence of silent cerebral infarction in Japanese patients with type 2 diabetes. Atherosclerosis, 2012, 222(2): 490–494. pmid:22460047
    • 46. YU H, YANG R T, WANG S Y, et al. Metformin use and risk of ischemic stroke in patients with type 2 diabetes: A cochort study. Journal Of Peking University (Health Sciences), 2023, 55(3): 456–464. https://doi.org/10.19723/j.issn.1671-167X.2023.03.011.
    • 47. CHENG Y Y, LEU H B, CHEN T J, et al. Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: a 4-year follow-up study. J Stroke Cerebrovasc Dis, 2014, 23(2): e99–105. pmid:24119365
    • 48. HA J, CHOI D W, KIM K Y, et al. Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case-control study. Cardiovasc Diabetol, 2021, 20(1): 152. pmid:34315501
    • 49. HUNG Y C, CHIU L T, HUANG H Y, et al. Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study. Cardiovasc Diabetol, 2020, 19(1): 94. pmid:32563247
    • 50. HSU P F, SUNG S H, CHENG H M, et al. Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin. J Clin Endocrinol Metab, 2018, 103(10): 3611–3619. pmid:30113697
    • 51. CHAN C W, YU C L, LIN J C, et al. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study. Cardiovasc Diabetol, 2018, 17(1): 20. pmid:29368615
    • 52. OU H T, CHANG K C, LI C Y, et al. Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes. Br J Clin Pharmacol, 2017, 83(7): 1556–1570. pmid:28109184
    • 53. ZGHEBI S S, STEINKE D T, RUTTER M K, et al. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records. Diabetes Obes Metab, 2016, 18(9): 916–924. pmid:27177784
    • 54. ADDERLEY N J, SUBRAMANIAN A, TOULIS K, et al. Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study. Diabetes Care, 2020, 43(8): 1868–1877. pmid:32345651
    • 55. ZHOU J, ZHANG G, CHANG C, et al. Metformin versus sulphonylureas for new onset atrial fibrillation and stroke in type 2 diabetes mellitus: a population-based study. Acta Diabetol, 2022, 59(5): 697–709. pmid:35112189
    • 56. LIN T K, CHEN Y H, HUANG J Y, et al. Sodium-glucose co-transporter-2 inhibitors reduce the risk of new-onset stroke in patients with type 2 diabetes: A population-based cohort study. Front Cardiovasc Med, 2022, 9: 966708. pmid:36035934
    • 57. ZIMMERMAN R S, HOBBS T M, WELLS B J, et al. Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system. Diabetes Obes Metab, 2017, 19(11): 1555–1561. pmid:28407414
    • 58. OTTO T, DIESING J, BORCHERT J, et al. Age-dependent prevalence of type 2 diabetes, cardiovascular risk profiles and use of diabetes drugs in Germany using health claims data. Diabetes Obes Metab, 2023, 25(3): 767–775. pmid:36457132
    • 59. SATTAR N, RAWSHANI A, FRANZéN S, et al. Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks. Circulation, 2019, 139(19): 2228–2237. pmid:30955347
    • 60. NANAYAKKARA N, CURTIS A J, HERITIER S, et al. Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. Diabetologia, 2021, 64(2): 275–287. pmid:33313987
    • 61. PETERS S A, HUXLEY R R, WOODWARD M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet, 2014, 383(9933): 1973–1980. pmid:24613026
    • 62. LI Y, GUO C, CAO Y. Secular incidence trends and effect of population aging on mortality due to type 1 and type 2 diabetes mellitus in China from 1990 to 2019: findings from the Global Burden of Disease Study 2019. BMJ Open Diabetes Res Care, 2021, 9(2): e002529. pmid:34732399
    • 63. JIA G, SOWERS J R. Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease. Hypertension, 2021, 78(5): 1197–1205. pmid:34601960
    • 64. CASTELBLANCO E, GRANADO-CASAS M, HERNáNDEZ M, et al. Diabetic retinopathy predicts cardiovascular disease independently of subclinical atherosclerosis in individuals with type 2 diabetes: A prospective cohort study. Front Cardiovasc Med, 2022, 9: 945421. pmid:36407461
    • 65. JEONG S M, YOO J E, PARK J, et al. Smoking behavior change and risk of cardiovascular disease incidence and mortality in patients with type 2 diabetes mellitus. Cardiovasc Diabetol, 2023, 22(1): 193. pmid:37516874
    • 66. PAN A, WANG Y, TALAEI M, et al. Relation of Smoking With Total Mortality and Cardiovascular Events Among Patients With Diabetes Mellitus: A Meta-Analysis and Systematic Review. Circulation, 2015, 132(19): 1795–1804. pmid:26311724
    • 67. ZHAO Y, QIE R, HAN M, et al. Association of BMI with cardiovascular disease incidence and mortality in patients with type 2 diabetes mellitus: A systematic review and dose-response meta-analysis of cohort studies. Nutr Metab Cardiovasc Dis, 2021, 31(7): 1976–1984. pmid:33965298
    • 68. VERGèS B. Pathophysiology of diabetic dyslipidaemia: where are we?. Diabetologia, 2015, 58(5): 886–899. pmid:25725623
    • 69. YUN J S, KO S H. Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. Metabolism, 2021, 123: 154838. pmid:34333002
    • 70. CAHN A, WIVIOTT S D, MOSENZON O, et al. Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. Diabetes Care, 2022, 45(4): 938–946. pmid:35015847
    • 71. RAWSHANI A, RAWSHANI A, FRANZéN S, et al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med, 2018, 379(7): 633–644. pmid:30110583
    • 72. SCHEEN A J. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Circ Res, 2018, 122(10): 1439–1459. https://doi.org/10.1161/CIRCRESAHA.117.311588.
    • 73. MOHAMMEDI K, WOODWARD M, MARRE M, et al. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes. Cardiovasc Diabetol, 2017, 16(1): 95. pmid:28750645
    • 74. BROWNRIGG J R, HUGHES C O, BURLEIGH D, et al. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol, 2016, 4(7): 588–597. pmid:27216886
    • 75. SCHEEN A J. Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Metab, 2022, 48(6): 101390. pmid:36170946
    • 76. MA C X, MA X N, GUAN C H, et al. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol, 2022, 21(1): 74. pmid:35568946
    • 77. STITZIEL N O, KANTER J E, BORNFELDT K E. Emerging Targets for Cardiovascular Disease Prevention in Diabetes. Trends Mol Med, 2020, 26(8): 744–757. pmid:32423639
    • 78. MATTHEWS D R, PALDáNIUS P M, PROOT P, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet, 2019, 394(10208): 1519–1529. pmid:31542292
    • 79. DAVIES M J, ARODA V R, COLLINS B S, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2022, 65(12): 1925–1966. pmid:36151309